Hiroki Ishibashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroki Ishibashi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Iwahashi
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
5 shared publications - Masashi Takano
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
5 shared publications - Morikazu Miyamoto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
5 shared publications - Takahiro Sakamoto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
5 shared publications - Hiroaki Soyama
Department of Obstetrics and Gynecology, Takanohara Central Hospital
3 shared publications - Hiroko Matsuura
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, 359-8513, Japan
3 shared publications
Latest Publications
- 21 October 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (11) , e70530
Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity
Aim: To develop and internally validate a pretreatment quantitative magnetic resonance imaging‐based predictive model for uterine fibroid volume reduction following gonadotropin‐releasing hormone antagonist therapy. Methods: In this single‐center retrospective study, 106 women with uterine fibroids treated with relugolix underwent pre‐ and intratreatment magnetic resonance imaging. The dominant fibroid was assessed for T2‐weighted imaging fibroid‐to‐iliopsoas signal intensity ratio, apparent diffusion coefficient, flow voids, and fibroid location. The primary outcome was a ≥ 30% reduction in dominant fibroid volume between pre and intratreatment magnetic resonance imaging. Eight baseline variables were entered into a Least Absolute Shrinkage and Selection Operator‐penalized logistic regression model with bootstrap internal validation. Results: Sixty patients (56.6%) achieved a ≥ 30% volume reduction. In the univariate analyses, a higher T2‐weighted imaging signal intensity ratio and location were significantly associated with response. A purely data‐driven Least Absolute Shrinkage and Selection Operator model retained two predictors: dichotomized T2‐weighted imaging signal intensity ratio and location. A T2‐weighted imaging ratio ≥ 2.0 was the strongest positive predictor, whereas subserosal and cervical locations showed negative associations and submucosal location showed a slight positive association relative to intramural fibroids. The model showed moderate discrimination (apparent area under the receiver operating characteristic curve, 0.746; optimism‐corrected area, 0.671) with acceptable calibration. Conclusions: Quantitative pretreatment T2‐weighted imaging (ratio ≥ 2.0) is strongly associated with fibroid volume reduction under gonadotropin‐releasing hormone antagonist therapy. An internally validated Least Absolute Shrinkage and Selection Operator‐based model incorporating T2‐weighted imaging signal intensity and location may aid individualized treatment selection and preoperative planning.
- 21 October 2026
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (11) , e70530
Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity
Aim: To develop and internally validate a pretreatment quantitative magnetic resonance imaging‐based predictive model for uterine fibroid volume reduction following gonadotropin‐releasing hormone antagonist therapy. Methods: In this single‐center retrospective study, 106 women with uterine fibroids treated with relugolix underwent pre‐ and intratreatment magnetic resonance imaging. The dominant fibroid was assessed for T2‐weighted imaging fibroid‐to‐iliopsoas signal intensity ratio, apparent diffusion coefficient, flow voids, and fibroid location. The primary outcome was a ≥ 30% reduction in dominant fibroid volume between pre and intratreatment magnetic resonance imaging. Eight baseline variables were entered into a Least Absolute Shrinkage and Selection Operator‐penalized logistic regression model with bootstrap internal validation. Results: Sixty patients (56.6%) achieved a ≥ 30% volume reduction. In the univariate analyses, a higher T2‐weighted imaging signal intensity ratio and location were significantly associated with response. A purely data‐driven Least Absolute Shrinkage and Selection Operator model retained two predictors: dichotomized T2‐weighted imaging signal intensity ratio and location. A T2‐weighted imaging ratio ≥ 2.0 was the strongest positive predictor, whereas subserosal and cervical locations showed negative associations and submucosal location showed a slight positive association relative to intramural fibroids. The model showed moderate discrimination (apparent area under the receiver operating characteristic curve, 0.746; optimism‐corrected area, 0.671) with acceptable calibration. Conclusions: Quantitative pretreatment T2‐weighted imaging (ratio ≥ 2.0) is strongly associated with fibroid volume reduction under gonadotropin‐releasing hormone antagonist therapy. An internally validated Least Absolute Shrinkage and Selection Operator‐based model incorporating T2‐weighted imaging signal intensity and location may aid individualized treatment selection and preoperative planning.
- 14 May 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (2) , 882-884
The hot‐sand technique: A novel approach to prevent balloon damage during the hot‐dog method
- 14 May 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (2) , 882-884
The hot‐sand technique: A novel approach to prevent balloon damage during the hot‐dog method
- Open Access
- 8 January 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (1) , 327-334
Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study
Background/Aim: Pancreaticobiliary maljunction (PBM), a disease with reflux of pancreatic and bile juice in the pancreaticobiliary tract, is a high-risk factor for biliary tract cancer. The aim of this study was to investigate the mechanism of carcinogenesis in PBM using a metabolomics analysis of bile sampled during surgery. Patients and Methods: Three patients with PBM without biliary tract cancer, four patients with extrahepatic bile duct cancer (EHBC), and three controls with benign disease were enrolled. Metabolomics analysis of bile samples was performed using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to discriminate the amino acid and lipidomic profiles. Results: The principal component analysis in the capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry revealed similar metabolites in patients with PBM and those with EHBC; furthermore, there was a clear difference between patients with PBM or EHBC compared to controls. The amino acid profiles revealed the following 20 potential carcinogenic candidates for PBM: isoleucine, phenylalanine, tyrosine, leucine, tryptophan, arginine, lysine, valine, asparagine, methionine, aspartic acid, serine, threonine, histidine, glutamine, alanine, proline, glutamic acid, and pyruvic acid. The lipidomic profiles revealed the following 11 carcinogenic candidates: lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidyl glycerol, lysophosphatidyl glycerol, triacylglycerol, diacylglycerol, ceramide, sphyngomyeline, fatty acid, hyperforin, and vitamin D. Among these characteristic metabolites, the branched-chain amino acids, methionine and lysophosphatidylcholine are known to be related to carcinogenesis. Conclusion: The bile metabolites were extremely similar in patients with PBM and those with EHBC. Furthermore, amino acid and lipid metabolism was markedly different in patients with PBM or EHBC compared to healthy controls.
- 8 January 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (1) , 327-334
Open AccessBile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study
Background/Aim: Pancreaticobiliary maljunction (PBM), a disease with reflux of pancreatic and bile juice in the pancreaticobiliary tract, is a high-risk factor for biliary tract cancer. The aim of this study was to investigate the mechanism of carcinogenesis in PBM using a metabolomics analysis of bile sampled during surgery. Patients and Methods: Three patients with PBM without biliary tract cancer, four patients with extrahepatic bile duct cancer (EHBC), and three controls with benign disease were enrolled. Metabolomics analysis of bile samples was performed using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to discriminate the amino acid and lipidomic profiles. Results: The principal component analysis in the capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry revealed similar metabolites in patients with PBM and those with EHBC; furthermore, there was a clear difference between patients with PBM or EHBC compared to controls. The amino acid profiles revealed the following 20 potential carcinogenic candidates for PBM: isoleucine, phenylalanine, tyrosine, leucine, tryptophan, arginine, lysine, valine, asparagine, methionine, aspartic acid, serine, threonine, histidine, glutamine, alanine, proline, glutamic acid, and pyruvic acid. The lipidomic profiles revealed the following 11 carcinogenic candidates: lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidyl glycerol, lysophosphatidyl glycerol, triacylglycerol, diacylglycerol, ceramide, sphyngomyeline, fatty acid, hyperforin, and vitamin D. Among these characteristic metabolites, the branched-chain amino acids, methionine and lysophosphatidylcholine are known to be related to carcinogenesis. Conclusion: The bile metabolites were extremely similar in patients with PBM and those with EHBC. Furthermore, amino acid and lipid metabolism was markedly different in patients with PBM or EHBC compared to healthy controls.
- 15 June 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (12) , 1657-1665
The use of magnetic resonance imaging to predict placenta previa with placenta accreta spectrum
Introduction: Massive hemorrhage due to placenta previa with placenta accreta spectrum is associated with high maternal mortality and morbidity. Therefore, accurate prediction of placenta previa with placenta accreta spectrum is essential; magnetic resonance imaging (MRI) is a useful tool for this purpose. This study investigated novel predictors of anterior and posterior placenta previa with placenta accreta spectrum using MRI.Material and methods: This was a retrospective study at a tertiary obstetrics hospital in Japan. The singleton patients with placenta previa who were scanned with MRI prenatally and had a cesarean section at our institution between 2007 and 2018 were included. The prediction of anterior and posterior placenta previa with placenta accreta spectrum was evaluated using four MRI findings: heterogeneous signals in the placenta, dark T2‐weighted intraplacental bands, myometrial thinning or interruption, and focal uterine bulging. The prediction of posterior placenta previa with placenta accreta spectrum was performed using the quantification of cervical varicosities, which were defined as the ratio of the distance between the minimum distance from the most dorsal cervical varicosities (a) to the deciduous and amniotic placenta (b) on a sagittal image.Results: Among 202 patients, 14 (6.9%) patients were pathologically diagnosed as having placenta accreta spectrum. Further, 38 (18.8%) patients had anterior placenta previa and 164 (81.2%) patients had posterior placenta previa. When anterior placenta previa with placenta accreta spectrum was predicted using at least one of the four MRI findings, the sensitivity and specificity of the anterior placenta previa with placenta accreta spectrum were 87.5% and 86.7%, respectively. In contrast, the sensitivity and specificity of posterior placenta previa with placenta accreta spectrum were 42.9% and 96.2%, respectively. But when the A/B ratio was set at 0.20, the sensitivity and specificity of the prediction for posterior placenta previa with placenta accreta spectrum using cervical varicosities were 100.0% and 89.2%, respectively.Conclusions: The findings of MRI to predict the anterior placenta previa with placenta accreta spectrum were different from posterior placenta previa. The cervical varicosities may be useful in predicting posterior placenta previa with placenta accreta spectrum.
- 15 June 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (12) , 1657-1665
The use of magnetic resonance imaging to predict placenta previa with placenta accreta spectrum
Introduction: Massive hemorrhage due to placenta previa with placenta accreta spectrum is associated with high maternal mortality and morbidity. Therefore, accurate prediction of placenta previa with placenta accreta spectrum is essential; magnetic resonance imaging (MRI) is a useful tool for this purpose. This study investigated novel predictors of anterior and posterior placenta previa with placenta accreta spectrum using MRI.Material and methods: This was a retrospective study at a tertiary obstetrics hospital in Japan. The singleton patients with placenta previa who were scanned with MRI prenatally and had a cesarean section at our institution between 2007 and 2018 were included. The prediction of anterior and posterior placenta previa with placenta accreta spectrum was evaluated using four MRI findings: heterogeneous signals in the placenta, dark T2‐weighted intraplacental bands, myometrial thinning or interruption, and focal uterine bulging. The prediction of posterior placenta previa with placenta accreta spectrum was performed using the quantification of cervical varicosities, which were defined as the ratio of the distance between the minimum distance from the most dorsal cervical varicosities (a) to the deciduous and amniotic placenta (b) on a sagittal image.Results: Among 202 patients, 14 (6.9%) patients were pathologically diagnosed as having placenta accreta spectrum. Further, 38 (18.8%) patients had anterior placenta previa and 164 (81.2%) patients had posterior placenta previa. When anterior placenta previa with placenta accreta spectrum was predicted using at least one of the four MRI findings, the sensitivity and specificity of the anterior placenta previa with placenta accreta spectrum were 87.5% and 86.7%, respectively. In contrast, the sensitivity and specificity of posterior placenta previa with placenta accreta spectrum were 42.9% and 96.2%, respectively. But when the A/B ratio was set at 0.20, the sensitivity and specificity of the prediction for posterior placenta previa with placenta accreta spectrum using cervical varicosities were 100.0% and 89.2%, respectively.Conclusions: The findings of MRI to predict the anterior placenta previa with placenta accreta spectrum were different from posterior placenta previa. The cervical varicosities may be useful in predicting posterior placenta previa with placenta accreta spectrum.
- 28 May 2020
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 26 (4) , 2299-2306
Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma
The aim of this study was to investigate the association between the clinicopathologic factors and either expression or co-expression of mesothelin and cancer antigen (CA) 125 in endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Between 1990 and 2017, patients with endometrial serous carcinoma and mixed carcinoma including serous carcinoma treated by total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either expression or co-expression of mesothelin and CA125 was evaluated by immunochemical analysis and the clinico-pathological features were retrospectively examined. Among the 40 patients included, 19, 31, and 18 patients exhibited single positive mesothelin, single positive CA125, and positive co-expression, respectively. The expression of mesothelin and CA125 was observed to be positively associated (p = 0.021). There was no significant association of age and FIGO stage with individual mesothelin or CA125 expression or their co-expression. Overall survival (OS), but not progression-free survivals (PFS), of only mesothelin-positive patients was worse (p = 0.024). Hence, OS and PFS of patients with positive co-expression were worse (PFS: p = 0.043, OS: p = 0.012). In multivariate analysis, single mesothelin expression and single CA125 expression did not lead to worse prognosis. However, positive co-expression was the worst prognostic factor for OS (hazard ratio: 3.32, p = 0.039). Co-expression of mesothelin and CA125 may accurately predict OS in endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Further studies should examine this relationship.
- 28 May 2020
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 26 (4) , 2299-2306
Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma
The aim of this study was to investigate the association between the clinicopathologic factors and either expression or co-expression of mesothelin and cancer antigen (CA) 125 in endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Between 1990 and 2017, patients with endometrial serous carcinoma and mixed carcinoma including serous carcinoma treated by total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either expression or co-expression of mesothelin and CA125 was evaluated by immunochemical analysis and the clinico-pathological features were retrospectively examined. Among the 40 patients included, 19, 31, and 18 patients exhibited single positive mesothelin, single positive CA125, and positive co-expression, respectively. The expression of mesothelin and CA125 was observed to be positively associated (p = 0.021). There was no significant association of age and FIGO stage with individual mesothelin or CA125 expression or their co-expression. Overall survival (OS), but not progression-free survivals (PFS), of only mesothelin-positive patients was worse (p = 0.024). Hence, OS and PFS of patients with positive co-expression were worse (PFS: p = 0.043, OS: p = 0.012). In multivariate analysis, single mesothelin expression and single CA125 expression did not lead to worse prognosis. However, positive co-expression was the worst prognostic factor for OS (hazard ratio: 3.32, p = 0.039). Co-expression of mesothelin and CA125 may accurately predict OS in endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Further studies should examine this relationship.
- 11 April 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5) , 941-947
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine
Purpose The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome. Methods Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified. Serum VEGF levels at the first and second treatment cycle were measured by ELISA. All patients were categorized into two groups—patients with > 50% decrease in serum VEGF-A levels (Group A) and patients with < 50% decrease serum VEGF-A levels (Group B). The association between clinical outcome and serum VEGF levels was investigated between the two groups. Results Among 18 patients, 10 were in Group A and 8 in Group B. Group A exhibited a lower response rate (0% vs.75% p < 0.01) and clinical benefit rate (60% vs.100% p = 0.02) than Group B. The median serum VEGF-A level of Group A before the first cycle of Bev-Gem therapy was higher than that in Group B (61.2 vs. 3.7 pg/mL, p < 0.01). Group A exhibited worse PFS (7 vs., 10 months, p < 0.01) and OS (17 vs. 26 months, p = 0.04) than Group B. There were more patients with > 10% increase in serum VEGF-B levels in Group A than in Group B (p < 0.01). Conclusion The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results.
- 11 April 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5) , 941-947
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine
Purpose The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome. Methods Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified. Serum VEGF levels at the first and second treatment cycle were measured by ELISA. All patients were categorized into two groups—patients with > 50% decrease in serum VEGF-A levels (Group A) and patients with < 50% decrease serum VEGF-A levels (Group B). The association between clinical outcome and serum VEGF levels was investigated between the two groups. Results Among 18 patients, 10 were in Group A and 8 in Group B. Group A exhibited a lower response rate (0% vs.75% p < 0.01) and clinical benefit rate (60% vs.100% p = 0.02) than Group B. The median serum VEGF-A level of Group A before the first cycle of Bev-Gem therapy was higher than that in Group B (61.2 vs. 3.7 pg/mL, p < 0.01). Group A exhibited worse PFS (7 vs., 10 months, p < 0.01) and OS (17 vs. 26 months, p = 0.04) than Group B. There were more patients with > 10% increase in serum VEGF-B levels in Group A than in Group B (p < 0.01). Conclusion The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results.
- 9 May 2019
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (10) , 1273-1283
Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.
- 9 May 2019
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (10) , 1273-1283
Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- 2 March 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (5) , 809-814
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
To compare a cohort of patients with platinum-resistant recurrent ovarian cancer (PROC) treated with bevacizumab and gemcitabine (Bev–Gem) to that of patients treated only with gemcitabine (Gem).
- 1 January 1998
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 21 (2) , 147-151
New consecutive high-dose chemotherapy modality with fractionated blood stem cell support in the treatment of high-risk pediatric solid tumors: a feasibility study
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.
- 1 January 1998
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 21 (2) , 147-151
New consecutive high-dose chemotherapy modality with fractionated blood stem cell support in the treatment of high-risk pediatric solid tumors: a feasibility study
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.